- Home
- ENTX vs CODA Comparison
ENTX vs CODA Comparison
Compare ENTX & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- CODA
- Stock Information
- Founded
- ENTX 2010
- CODA 1994
- Country
- ENTX Israel
- CODA United States
- Employees
- ENTX N/A
- CODA N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- CODA Industrial Machinery/Components
- Sector
- ENTX Health Care
- CODA Industrials
- Exchange
- ENTX Nasdaq
- CODA Nasdaq
- Market Cap
- ENTX 104.0M
- CODA 88.7M
- IPO Year
- ENTX 2018
- CODA N/A
- Fundamental
- Price
- ENTX $1.86
- CODA $8.16
- Analyst Decision
- ENTX Strong Buy
- CODA Strong Buy
- Analyst Count
- ENTX 1
- CODA 1
- Target Price
- ENTX $10.00
- CODA $11.00
- AVG Volume (30 Days)
- ENTX 37.4K
- CODA 65.1K
- Earning Date
- ENTX 08-08-2025
- CODA 06-16-2025
- Dividend Yield
- ENTX N/A
- CODA N/A
- EPS Growth
- ENTX N/A
- CODA 21.86
- EPS
- ENTX N/A
- CODA 0.30
- Revenue
- ENTX $223,000.00
- CODA $22,758,966.00
- Revenue This Year
- ENTX N/A
- CODA $11.64
- Revenue Next Year
- ENTX N/A
- CODA $14.53
- P/E Ratio
- ENTX N/A
- CODA $27.34
- Revenue Growth
- ENTX N/A
- CODA 24.78
- 52 Week Low
- ENTX $1.41
- CODA $5.76
- 52 Week High
- ENTX $2.79
- CODA $9.89
- Technical
- Relative Strength Index (RSI)
- ENTX 43.10
- CODA 64.18
- Support Level
- ENTX $1.91
- CODA $7.78
- Resistance Level
- ENTX $2.04
- CODA $8.46
- Average True Range (ATR)
- ENTX 0.14
- CODA 0.60
- MACD
- ENTX -0.01
- CODA 0.07
- Stochastic Oscillator
- ENTX 13.64
- CODA 72.99
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.